MedTrace Logo

Effect of Stellate Ganglion Block on Meniere's Disease

NCT01574313 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-04-11

No results posted yet for this study

Summary

Stellate ganglion block (SGB) has been the alternative treatment of Meniere's disease for years. However, objective evidence of the effect of SGB was still lack. The investigators conducted a randomized controlled study to examine the immediate effects of SGB in SP/AP of electrocochleography (ECoG).

Conditions

  • Vertigo
  • Meniere Disease

Interventions

PROCEDURE

stellate ganglion block

stellate ganglion block

DRUG

0.25mg, fludiazine

0.25mg of erispan@ (fludiazine), p.o. one dose only.

DRUG

25mg cephadol@ (diphenidol)

25mg cephadol@ (diphenidol) p.o. one dose only.

DRUG

200mg kentons@ (tocopherol nicotinate).

200mg kentons@ (tocopherol nicotinate) p.o. one dose only.

Sponsors & Collaborators

  • Chi Mei Medical Hospital

    lead OTHER

Principal Investigators

  • Yung-Song Lin, M.D. · Chi Mei Medical Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-04-30
Completion
2012-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574313 on ClinicalTrials.gov